Autologous T cells therapy(Unicar-Therapy)

N/A

Report date: 2023/04/04 14:18:13

Base Information

Drug NameAutologous T cells therapy(Unicar-Therapy)
Drug Alias NameAnti-PSMA/PSCA chimeric antigen receptor T cell therapy(Unicar-Therapy)PD-1 silent PSMA/PSCA targeted CAR-T cell therapy(Unicar-Therapy)
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsProstate-Specific Membrane Antigen modulatorsImmunologic cytotoxicity
TargetsProstate-Specific Membrane Antigen
Therapy Area/IndicationsProstatic Neoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Unicar-Therapy Bio-Medicine Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsProstatic Neoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A